Product Description
PG102P, which is prepared from Actinidia arguta, has an immune-modulating effect on pruritus.
Mechanisms of Action: Unknown
Novel Mechanism: No
Modality: N/A
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Seoul National University Boramae Hospital
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
SNUG | N/A |
Completed |
Pruritus |
2019-01-31 |